Amneal Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 5c; Offers FY22 Guidance
November 4, 2022 6:02 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $546 million versus the consensus estimate of $564.24 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.68. Amneal... More
